Technology Platforms
Acura is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing the Company’s proprietary LIMITX™, IMPEDE® and AVERSION® Technology platforms. Acura’s products and product candidates are based on widely-used commercial products and do not alter the safety and efficacy of the active pharmaceutical ingredients that are intended to effectively treat the patient while simultaneously discouraging common methods of product tampering and abuse.
LIMITX™ Technology addresses abuse by excess oral consumption of multiple tablets by limiting the release of the active ingredient when multiple tablets are swallowed. In addition, LIMITX™ is also expected to exhibit barriers to abuse by snorting and injection. More…
The Company’s IMPEDE® Technology platform is an advanced polymer matrix that is used in NEXAFED®, Acura’s pseudoephedrine (PSE) tablet product, to limit or disrupt the extraction of PSE from tablets for conversion into the illicit drug methamphetamine. More…
Acura’s AVERSION® Technology platform has been successfully utilized in developing multiple abuse deterrent opioid analgesic product candidates. The first product commercialized utilizing AVERSION® Technology is OXAYDO® (oxycodone hydrochloride) Tablets CII. More…
Acura has multiple abuse deterrent products in development utilizing each of its technology platforms with a primary focus on LIMITX™ and IMPEDE® technology products.